Fuente: Prohibición Partners Lugar: Uncategorized The global medical cannabis market has shifted more in the past 12 months than in the previous five years combined. Canada rewrote the export record books, Germany doubled down on patient access following legalisation, and telemedicine quietly became the default way most patients around the world access medical cannabis.



The Global Medical Cannabis Market Review 2026 captures all of this in one free-to-download report. It is the most comprehensive overview of international export markets and patient markets that Prohibition Partners has published to date, and the data it contains is already shaping commercial and investment decisions across the industry.



Here are five findings worth paying attention to.



1. Canada exported 275,343kg of medical cannabis in 2025 — more than every other country combined



This is the number that defines the current export landscape. Canadian medical cannabis exports grew by over 250% year-on-year, reaching 275,343kg in 2025. To put that in context, no other exporting nation comes close to matching this volume individually, let alone collectively.



The structural advantage driving this is straightforward: Canada has a mature domestic adult-use market that gives its licensed producers scale, infrastructure, and cost efficiencies that cultivators in Israel, Portugal, and other competing export nations simply cannot replicate. The report explores how this dominance is reshaping competitive dynamics for producers across the global supply chain.



2. Germany’s medical cannabis market grew 155% to an estimated $997 million



Germany is now the largest medical cannabis patient market outside North America, with an estimated market value approaching $997 million in 2025. That represents 155% year-on-year growth — a direct consequence of regulatory changes that removed cannabis from the narcotics schedule and simplified prescribing pathways.



The result has been a significant increase in prescribing volumes, a growing network of 35 identified teleclinics, and an influx of new commercial operators entering the market. For anyone evaluating the European opportunity, Germany is the market that sets the benchmark. Our European cannabis markets coverage provides broader context on how Germany’s trajectory compares to its European peers.



3. The UK market doubled to $298 million — and the growth trajectory is steepening



The UK medical cannabis market reached an estimated $298 million in 2025, representing 104% year-on-year growth. Patient volumes continue to expand, driven by 29 identified teleclinics and increasing awareness among both clinicians and patients.



What makes the UK particularly interesting from a commercial perspective is the pace of change. This is a market that barely existed five years ago and has now established itself as the second-largest medical cannabis patient market in Europe, behind Germany. The report examines the dynamics driving this growth, from product pricing trends to the competitive landscape among clinic operators.



Together, Germany and the UK account for the vast majority of European medical cannabis market activity. Understanding both is essential for any operator or investor with a European strategy.



4. Telemedicine is now the dominant access model in every major patient market



Across Australia (47 teleclinics), Germany (35), the UK (29), and Brazil (23), cannabis-specific teleclinics have become the primary pathway through which patients access medical cannabis. This is not a peripheral trend. In most major markets, telemedicine is the default model.



The pattern is remarkably consistent: each market sees a proliferation of digital-first clinic operators, followed by consolidation as a small number of dominant players capture the majority of patients. The report maps this dynamic across four continents, identifying the operators and the market structures that are emerging.



For product manufacturers and distributors, understanding the telemedicine landscape is commercially critical. These platforms increasingly influence which products are prescribed, how patients are onboarded, and where value accrues in the supply chain.



5. Portugal is becoming a processing hub rather than a primary cultivator



Portugal has long been regarded as one of Europe’s leading medical cannabis production countries. The data now tells a more nuanced story. In 2025, Portugal was likely a net importer of medical cannabis by volume, despite maintaining significant export figures. The country is increasingly functioning as a processing and re-exportation hub — importing bulk cannabis (predominantly from Canada), processing it, and exporting finished products into European patient markets.



This structural shift has significant implications for the European supply chain and for cultivators who have invested in Portuguese production capacity on the assumption that domestic cultivation would be the primary value driver.



What comes next



The Global Medical Cannabis Market Review 2026 covers all of the above in detail, alongside analysis of Australia, Israel, Brazil, Poland, Thailand, and France. It is free to download and provides the baseline intelligence that professionals across the industry need to inform their strategic planning.



For those who require more granular data — market sizing forecasts through to 2030, product-level pricing analysis, and competitive intelligence — Prohibition Partners has developed dedicated data packages for the UK and Germany.



Download the Global Medical Cannabis Market Review 2026
The post Five Takeaways from the Global Medical Cannabis Market Review 2026 appeared first on Prohibition Partners.